Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Neumora Therapeutics

31/07/2026 21:26

Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to  show no change in quarterly revenue when it reports  results on August 3 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Neumora Therapeutics Inc is for a loss of 24 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Neumora Therapeutics Inc is $5.00, about 203% above its last closing price of $1.65
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.30
-0.31
-0.30
Beat
3.2
Dec. 31 2026
-0.30
-0.33
-0.35
Missed
-7.5
Sep. 30 2025
-0.32
-0.33
-0.32
Beat
4.1​
Jun. 30 2025
-0.36
-0.37
-0.33
Beat
10.4
​​Mar. 31 2025
-0.35
-0.37
-0.42
Missed
-12.2
Dec. 31 2024
-0.46
-0.45
-0.37
Beat
17.1​
Sep. 30 2024
-0.38
-0.39
-0.45
Missed
-15.4
Jun. 30 2024
-0.38
-0.37
-0.37
Met
0.4
This summary was machine generated July 31 at 20:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)